(Q43242768)

17 November 2017

title

Current and emerging treatments for chronic lymphocytic leukaemia (English)

1 reference

17 November 2017

1 reference

1

Tadeusz Robak

1 reference

17 November 2017

2

Krzysztof Jamroziak

1 reference

17 November 2017

3

Pawel Robak

1 reference

17 November 2017

publication date

1 January 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

69

1 reference

17 November 2017

issue

17

1 reference

17 November 2017

page(s)

2415-2449

1 reference

https://scigraph.springernature.com/pub.10.2165/11319270-000000000-00000

17 November 2017

exact match

0 references

cites work

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11319270-000000000-00000

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11319270-000000000-00000

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11319270-000000000-00000

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

12 December 2020

Flavopiridol in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity

1 reference

12 December 2020

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

1 reference

12 December 2020

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

12 December 2020

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

12 December 2020

Novel purine nucleoside analogues for hematological malignancies

1 reference

12 December 2020

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized tria

1 reference

12 December 2020

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Oblimersen for the treatment of patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

12 December 2020

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

12 December 2020

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

1 reference

12 December 2020

Bendamustine: a new look at an old drug

1 reference

12 December 2020

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

1 reference

12 December 2020

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

1 reference

12 December 2020

Pathology of chronic lymphocytic leukemia: an update

1 reference

12 December 2020

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience

1 reference

12 December 2020

High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

1 reference

12 December 2020

Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

12 December 2020

Imatinib sensitizes CLL lymphocytes to chlorambucil

1 reference

12 December 2020

Treatment of elderly patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

12 December 2020

Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody

1 reference

12 December 2020

Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance

1 reference

12 December 2020

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders

1 reference

12 December 2020

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

1 reference

12 December 2020

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma

1 reference

12 December 2020

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia

1 reference

12 December 2020

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

1 reference

12 December 2020

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

12 December 2020

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

12 December 2020

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

1 reference

12 December 2020

Cellular immune therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

12 December 2020

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

1 reference

12 December 2020

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

1 reference

12 December 2020

The clinical and epidemiological burden of chronic lymphocytic leukaemia

1 reference

12 December 2020

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

1 reference

12 December 2020

The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.

1 reference

12 December 2020

Bendamustine in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia

1 reference

12 December 2020

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

12 December 2020

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

12 December 2020

Recent progress in the management of chronic lymphocytic leukemia

1 reference

12 December 2020

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

1 reference

12 December 2020

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

12 December 2020

Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

12 December 2020

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

1 reference

12 December 2020

1 reference

12 December 2020

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

12 December 2020

Novel immune-based treatment strategies for chronic lymphocytic leukemia

1 reference

12 December 2020

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

12 December 2020

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

12 December 2020

Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.

1 reference

12 December 2020

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

1 reference

12 December 2020

Maintenance therapy for low-grade lymphomas: has the time come?

1 reference

12 December 2020

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

12 December 2020

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

12 December 2020

Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment

1 reference

12 December 2020

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

12 December 2020

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

12 December 2020

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

12 December 2020

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

1 reference

12 December 2020

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

1 reference

12 December 2020

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

12 December 2020

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

1 reference

12 December 2020

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

1 reference

12 December 2020

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

12 December 2020

Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity

1 reference

12 December 2020

The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.

1 reference

12 December 2020

A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group

1 reference

12 December 2020

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

1 reference

12 December 2020

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

12 December 2020

Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro

1 reference

12 December 2020

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

1 reference

12 December 2020

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases.

1 reference

12 December 2020

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.

1 reference

12 December 2020

Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia

1 reference

12 December 2020

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

1 reference

12 December 2020

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

1 reference

12 December 2020

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

1 reference

12 December 2020

Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia

1 reference

12 December 2020

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

1 reference

12 December 2020

R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.

1 reference

12 December 2020

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

1 reference

12 December 2020

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

1 reference

12 December 2020

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

1 reference

12 December 2020

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

12 December 2020

Programmed anuclear cell death delimits platelet life span.

1 reference

12 December 2020

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

1 reference

12 December 2020

Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor

1 reference

12 December 2020

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

12 December 2020

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

1 reference

12 December 2020

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

1 reference

12 December 2020

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

12 December 2020

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Clinical staging of chronic lymphocytic leukemia

1 reference

12 December 2020

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

12 December 2020

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

12 December 2020

Rediscovering alemtuzumab: current and emerging therapeutic roles

1 reference

12 December 2020

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

1 reference

12 December 2020

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

12 December 2020

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

12 December 2020

Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

1 reference

12 December 2020

1 reference

12 December 2020

Targeted drugs in chronic myeloid leukemia.

1 reference

12 December 2020

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

12 December 2020

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

1 reference

12 December 2020

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

1 reference

12 December 2020

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

1 reference

12 December 2020

Stem cell transplantation in chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

12 December 2020

c-Abl Expression in Chronic Lymphocytic Leukemia Cells: Clinical and Therapeutic Implications

1 reference

12 December 2020

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

1 reference

12 December 2020

mTOR: the mammalian target of replication

1 reference

12 December 2020

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

12 December 2020

Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial

1 reference

12 December 2020

Chemistry and clinical biology of the bryostatins

1 reference

12 December 2020

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

1 reference

12 December 2020

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

12 December 2020

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

1 reference

12 December 2020

Chronic lymphocytic leukemia

1 reference

12 December 2020

Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.

1 reference

12 December 2020

Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

1 reference

12 December 2020

The role of stem cell transplantation in the management of chronic lymphocytic leukaemia

1 reference

12 December 2020

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

1 reference

12 December 2020

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

1 reference

12 December 2020

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial

1 reference

12 December 2020

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

12 December 2020

Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies

1 reference

12 December 2020

CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter study

1 reference

12 December 2020

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

12 December 2020

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

12 December 2020

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

1 reference

12 December 2020

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

1 reference

12 December 2020

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

12 December 2020

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

1 reference

12 December 2020

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity

1 reference

12 December 2020

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

12 December 2020

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

1 reference

12 December 2020

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

1 reference

12 December 2020

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

1 reference

12 December 2020

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

1 reference

12 December 2020

Alemtuzumab for B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies

1 reference

12 December 2020

Treatment of fludarabine-refractory chronic lymphocytic leukemia

1 reference

12 December 2020

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

1 reference

12 December 2020

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Clinical pharmacokinetics of everolimus

1 reference

12 December 2020

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

12 December 2020

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

1 reference

12 December 2020

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

1 reference

12 December 2020

Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis

1 reference

12 December 2020

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

1 reference

12 December 2020

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

1 reference

12 December 2020

Advances in chemotherapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy

1 reference

12 December 2020

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

1 reference

12 December 2020

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

1 reference

12 December 2020

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

12 December 2020

10.2165/11319270-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

17 November 2017

1053447347

0 references

Fatcat ID

release_vr3v6ngdzveyzjyzfijo66ewi4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vr3v6ngdzveyzjyzfijo66ewi4

24 November 2022

mapped directly with Wikidata item

1 reference